An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells.
暂无分享,去创建一个
Ho Jin Sung | Ji-Eun Jung | Eun-Ok Kim | In-Hoo Kim | Sue Goo Rhee | S. S. Koh | Ji Won Lee | S. Rhee | Y. Kim | Kyungho Choi | In-Hoo Kim | Sukyoung Kim | Yangsoon Lee | Sang Seok Koh | Yun-Hee Kim | Kyun Heo | Yangsoon Lee | Sukyoung Kim | Ju Young Moon | Kyungho Choi | Ji-Eun Jung | Eun-Ok Kim | H. J. Sung | K. Heo | J. Y. Moon
[1] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[2] Y F Hui,et al. Gemcitabine: a cytidine analogue active against solid tumors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[3] T. Yeatman,et al. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. , 2008, Cancer control : journal of the Moffitt Cancer Center.
[4] H. Ueno,et al. Adjuvant treatments for resectable pancreatic cancer , 2008, Journal of hepato-biliary-pancreatic surgery.
[5] C. Rocha-Lima,et al. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. , 2010, World journal of gastroenterology.
[6] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[8] J. Jeekel,et al. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? , 2005, Langenbeck's Archives of Surgery.
[9] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[10] H. Iwasaki,et al. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. , 1997, Blood.
[11] G. Bepler,et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.
[12] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[13] S. S. Koh,et al. PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression , 2010, Oncogene.
[14] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[15] Andrew D Ellington,et al. Aptamer therapeutics advance. , 2006, Current opinion in chemical biology.
[16] P. Chames,et al. Therapeutic Antibodies for the Treatment of Pancreatic Cancer , 2010, TheScientificWorldJournal.
[17] D. Bunka,et al. Development of aptamer therapeutics. , 2010, Current opinion in pharmacology.
[18] N. Lemoine,et al. Novel therapies for pancreatic cancer: setbacks and progress. , 2010, Future oncology.
[19] M. Blank,et al. Aptamers as tools for target validation. , 2005, Current opinion in chemical biology.
[20] F. Ducongé,et al. Aptamers against extracellular targets for in vivo applications. , 2005, Biochimie.
[21] N. Janjić,et al. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.
[22] P. Philip,et al. Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. , 2009, Gastrointestinal cancer research : GCR.
[23] L. Gelbert,et al. An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.
[24] Bauke Ylstra,et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.
[25] Young Woo Park,et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation , 2011, Oncogene.
[26] I. Nomikos,et al. Current Surgical Aspects of Palliative Treatment for Unresectable Pancreatic Cancer , 2011, Cancers.
[27] Amy C Yan,et al. Aptamers and aptamer targeted delivery , 2009, RNA biology.
[28] R. Brand,et al. Chemoprevention strategies for pancreatic cancer , 2010, Nature Reviews Gastroenterology &Hepatology.
[29] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Dongling Yang,et al. Knockdown of CD146 reduces the migration and proliferation of human endothelial cells , 2006, Cell Research.
[31] S. S. Koh,et al. Pancreatic adenocarcinoma up‐regulated factor (PAUF), a novel up‐regulated secretory protein in pancreatic ductal adenocarcinoma , 2009, Cancer science.